Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orismilast PK and Safety in Healthy Japanese Men
NCT03231124Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Jul 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Psoriasis vulgaris (PV) comparing Orismilast with Placebo (2 arms). Primary endpoints: Area under the plasma concentration-time curve from zero to 12 hour, Time to reach maximum observed plasma concentration at Day 12 and 1 more. Started Jul 2017; status: completed.
02
Drugs
orismilast
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT03231124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231124.